Alzheimer’s - Hypotheses & Drug Targets
The blood-brain barrier (BBB) is a physical barrier that keeps the extracellular fluid of the brain separate from the bloodstream.
July 31, 2023
by David Orchard-Webb
NIH study says repurposed cancer therapies beneficial for Alzheimer’s
Scientists from the US National Institutes of Health (NIH) unit National Institute on Aging (NIA) have found that present and developing therapies for cancer could potentially...
November 12, 2021
by Pharmaceutical-Technology
Thinking impaired in 60% of COVID-19 survivors
In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the ...
August 2, 2021
by worldpharmanews
Alzheimer’s treatment lowers tau by nearly 50 percent in Phase I trials
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.
July 30, 2021
by europeanpharmaceuticalreview
Former FDA adviser calls for wider probe into Biogen Alzheimer’s drug approval
A federal probe of the US Food and Drug Administration’s approval of a controversial new Alzheimer’s disease drug should look into why that decision was made without clear evidence of patient benefit, a former adviser to the agency said 20th.
July 22, 2021
by expresspharma
Biogen gets US FDA accelerated approval for Aduhelm to treat Alzheimer’s
It is the first new treatment approved for Alzheimer's since 2003 and is the first therapy that targets the fundamental pathophysiology of the disease.
June 9, 2021
by expresspharma
FDA Approves Aducanumab To Treat Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has approved aducanumab, the first drug that slows Alzheimer's disease. Aducanumab is also the first novel therapy for Alzheimer’s disease approved since 2003.
June 9, 2021
by contractpharma
Alzheimer’s drug designed using Exscientia’s AI technology enters clinic
An Alzheimer’s disease drug candidate designed using Exscientia’s artificial intelligence (AI) technology has entered Phase I clinical testing, the company announced May 13.
May 17, 2021
by pharmatimes
First AI designed Alzheimer’s drug to enter clinical trials
The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.
May 14, 2021
by europeanpharmaceuticalreview
Leukine® is beneficial to patients with mild-to-moderate Alzheimer’s, finds study
In a Phase II trial, Leukine® (sargramostim) significantly reduced biomarkers of neurodegeneration and improved cognitive function.
March 26, 2021
by europeanpharmaceuticalreview
Salbutamol significantly increases cerebral perfusion in proof-of-concept trial
In the Phase I trial, the beta-2 adrenoceptor agonist salbutamol significantly increased cerebral perfusion, a key biomarker in neurodegenerative disease.
March 17, 2021
by europeanpharmaceuticalreview
Cassava Sciences Enters Drug Supply Agreement with Evonik
Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam.
March 10, 2021
by contractpharma